

Jeremy Tomlinson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3913950/publications.pdf>

Version: 2024-02-01

178
papers

14,227
citations

25034

57
h-index

21540

114
g-index

184
all docs

184
docs citations

184
times ranked

13896
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of Weight Changes With Changes in Histological Features and Blood Markers in Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e538-e547.	4.4	12
2	Society for Endocrinology guidelines for testosterone replacement therapy in male hypogonadism. <i>Clinical Endocrinology</i> , 2022, 96, 200-219.	2.4	46
3	Metformin maintains intrahepatic triglyceride content through increased hepatic de novo lipogenesis. <i>European Journal of Endocrinology</i> , 2022, 186, 367-377.	3.7	12
4	Sex hormones, adiposity, and metabolic traits in men and women: a Mendelian randomisation study. <i>European Journal of Endocrinology</i> , 2022, 186, 407-416.	3.7	17
5	Is it time for chronopharmacology in NASH?. <i>Journal of Hepatology</i> , 2022, 76, 1215-1224.	3.7	20
6	AKR1D1 knockout mice develop a sex-dependent metabolic phenotype. <i>Journal of Endocrinology</i> , 2022, 253, 97-113.	2.6	7
7	Acute intermittent hypoxia drives hepatic de novo lipogenesis in humans and rodents. <i>Metabolism Open</i> , 2022, 14, 100177.	2.9	6
8	Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 755-769.	8.1	34
9	Is autonomous cortisol secretion sexually dimorphic?. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 473-475.	11.4	1
10	Increased systemic and adipose 11 β -HSD1 activity in idiopathic intracranial hypertension. <i>European Journal of Endocrinology</i> , 2022, 187, 323-333.	3.7	11
11	Clinical practice gaps and challenges in non-alcoholic steatohepatitis care: An international physician needs assessment. <i>Liver International</i> , 2022, 42, 1772-1782.	3.9	7
12	11 β -HSD1 Inhibition with AZD4017 Improves Lipid Profiles and Lean Muscle Mass in Idiopathic Intracranial Hypertension. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 174-187.	3.6	39
13	Differential activity and expression of human 5 β -reductase (AKR1D1) splice variants. <i>Journal of Molecular Endocrinology</i> , 2021, 66, 181-194.	2.5	3
14	The role of 5-reduction in physiology and metabolic disease: evidence from cellular, pre-clinical and human studies. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2021, 207, 105808.	2.5	9
15	International practice of corticosteroid replacement therapy in congenital adrenal hyperplasia: data from the I-CAH registry. <i>European Journal of Endocrinology</i> , 2021, 184, 553-563.	3.7	21
16	Systemic and adipocyte transcriptional and metabolic dysregulation in idiopathic intracranial hypertension. <i>JCI Insight</i> , 2021, 6, .	5.0	45
17	Extensive weight loss reduces glycan age by altering IgG N-glycosylation. <i>International Journal of Obesity</i> , 2021, 45, 1521-1531.	3.4	29
18	Gonadectomy in conditions affecting sex development: a registry-based cohort study. <i>European Journal of Endocrinology</i> , 2021, 184, 791-801.	3.7	9

#	ARTICLE	IF	CITATIONS
19	Sleep and liver disease: a bidirectional relationship. The Lancet Gastroenterology and Hepatology, 2021, 6, 850-863.	8.1	36
20	Relative Adipose Tissue Failure in Alström Syndrome Drives Obesity-Induced Insulin Resistance. Diabetes, 2021, 70, 364-376.	0.6	23
21	SP5.1.5 Bariatric surgery is associated with greater survival and metabolic health benefits than conventional medical management in people with NAFLD. British Journal of Surgery, 2021, 108, .	0.3	0
22	Glucocorticoids in pregnancy. Obstetric Medicine, 2020, 13, 62-69.	1.1	17
23	Plasma Renin Measurements are Unrelated to Mineralocorticoid Replacement Dose in Patients With Primary Adrenal Insufficiency. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 314-326.	3.6	30
24	Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management. Endocrine Reviews, 2020, 41, 66-117.	20.1	134
25	Sodium-glucose cotransporter 2 inhibition does not reduce hepatic steatosis in overweight, insulin-resistant patients without type 2 diabetes. JGH Open, 2020, 4, 433-440.	1.6	10
26	Perioperative corticosteroid supplementation for patients on therapeutic glucocorticoids: a national survey. Anaesthesia, 2020, 75, 1396-1398.	3.8	2
27	The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. American Journal of Physiology - Renal Physiology, 2020, 319, G345-G360.	3.4	20
28	Altered cortisol metabolism in individuals with HNF1A-MODY. Clinical Endocrinology, 2020, 93, 269-279.	2.4	4
29	Editorial: can urine-based metabolomics improve diagnosis of advanced fibrosis in NAFLD? Authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 51, 1205-1206.	3.7	0
30	Co-administration of 5 α -reductase Inhibitors Worsens the Adverse Metabolic Effects of Prescribed Glucocorticoids. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3316-e3328.	3.6	9
31	The A-ring reduction of 11-ketotestosterone is efficiently catalysed by AKR1D1 and SRD5A2 but not SRD5A1. Journal of Steroid Biochemistry and Molecular Biology, 2020, 202, 105724.	2.5	13
32	11 β -Hydroxysteroid dehydrogenase type 1 inhibition in idiopathic intracranial hypertension: a double-blind randomized controlled trial. Brain Communications, 2020, 2, fcz050.	3.3	46
33	Accurate non-invasive diagnosis and staging of non-alcoholic fatty liver disease using the urinary steroid metabolome. Alimentary Pharmacology and Therapeutics, 2020, 51, 1188-1197.	3.7	13
34	Guidelines for the management of glucocorticoids during the perioperative period for patients with adrenal insufficiency. Anaesthesia, 2020, 75, 654-663.	3.8	93
35	Fighting liver fat. Endocrine Connections, 2020, 9, R173-R186.	1.9	4
36	Glucocorticoids regulate AKR1D1 activity in human liver in vitro and in vivo. Journal of Endocrinology, 2020, 245, 207-218.	2.6	9

#	ARTICLE	IF	CITATIONS
37	Guidance for the prevention and emergency management of adult patients with adrenal insufficiency. <i>Clinical Medicine</i> , 2020, 20, 371-378.	1.9	44
38	Glucocorticoid Metabolism and Activation. , 2019, , 90-103.		3
39	AKR1D1 is a novel regulator of metabolic phenotype in human hepatocytes and is dysregulated in non-alcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2019, 99, 67-80.	3.4	52
40	Recovery of the Hypothalamo-Pituitary-Adrenal Axis After Transsphenoidal Adenectomy for Nonâ€“ACTH-Secreting Macroadenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 5316-5324.	3.6	19
41	Increased central adiposity and decreased subcutaneous adipose tissue 11Î²â€“hydroxysteroid dehydrogenase type 1 are associated with deterioration in glucose toleranceâ€“A longitudinal cohort study. <i>Clinical Endocrinology</i> , 2019, 91, 72-81.	2.4	9
42	A multidisciplinary approach to the management of NAFLD is associated with improvement in markers of liver and cardio-metabolic health. <i>Frontline Gastroenterology</i> , 2019, 10, 337-346.	1.8	48
43	Author's Reply: Does increased 11 Î² HSDâ€“1 activity induce adverse metabolic phenotype only in lean?. <i>Clinical Endocrinology</i> , 2019, 90, 849-850.	2.4	0
44	Human and murine steroid 5Î²-reductases (AKR1D1 and AKR1D4): insights into the role of the catalytic glutamic acid. <i>Chemico-Biological Interactions</i> , 2019, 305, 163-170.	4.0	8
45	AKR1D1 regulates glucocorticoid availability and glucocorticoid receptor activation in human hepatoma cells. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2019, 189, 218-227.	2.5	16
46	Hepatitis C virus infection is associated with hepatic and adipose tissue insulin resistance that improves after viral cure. <i>Clinical Endocrinology</i> , 2019, 90, 440-448.	2.4	16
47	Of mice and men: Is there a future for metformin in the treatment of hepatic steatosis?. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 749-760.	4.4	23
48	Very low calorie diets are associated with transient ventricular impairment before reversal of diastolic dysfunction in obesity. <i>International Journal of Obesity</i> , 2019, 43, 2536-2544.	3.4	12
49	PYY plays a key role in the resolution of diabetes following bariatric surgery in humans. <i>EBioMedicine</i> , 2019, 40, 67-76.	6.1	65
50	A unique androgen excess signature in idiopathic intracranial hypertension is linked to cerebrospinal fluid dynamics. <i>JCI Insight</i> , 2019, 4, .	5.0	55
51	A potential role for hepcidin in obesity-driven colorectal tumourigenesis. <i>Oncology Reports</i> , 2018, 39, 392-400.	2.6	6
52	Evaluating the Fat Distribution in Idiopathic Intracranial Hypertension Using Dual-Energy X-ray Absorptiometry Scanning. <i>Neuro-Ophthalmology</i> , 2018, 42, 99-104.	1.0	42
53	The 5-HT2C receptor agonist meta-chlorophenylpiperazine (mCPP) reduces palatable food consumption and BOLD fMRI responses to food images in healthy female volunteers. <i>Psychopharmacology</i> , 2018, 235, 257-267.	3.1	14
54	Prevalence and severity of nonâ€“alcoholic fatty liver disease are underestimated in clinical practice: impact of a dedicated screening approach at a large university teaching hospital. <i>Diabetic Medicine</i> , 2018, 35, 89-98.	2.3	35

#	ARTICLE	IF	CITATIONS
55	Treatment with PBI-4050 in patients with Alstr�m syndrome: study protocol for a phase 2, single-Centre, single-arm, open-label trial. BMC Endocrine Disorders, 2018, 18, 88.	2.2	15
56	PWE-075����Managing nafld via a multidisciplinary clinic approach improves liver health and is cost effective. , 2018, , .		0
57	Sex Differences in Hepatic De Novo Lipogenesis with Acute Fructose Feeding. Nutrients, 2018, 10, 1263.	4.1	35
58	Learning pharmacokinetic models for in vivo glucocorticoid activation. Journal of Theoretical Biology, 2018, 455, 222-231.	1.7	6
59	The Short Synacthen (Corticotropin) Test Can Be Used to Predict Recovery of Hypothalamo-Pituitary-Adrenal Axis Function. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 3050-3059.	3.6	48
60	Liver biochemical abnormalities in Turner syndrome: A comprehensive characterization of an adult population. Clinical Endocrinology, 2018, 89, 667-676.	2.4	21
61	The Endocrine and Metabolic Characteristics of a Large Bardet-Biedl Syndrome Clinic Population. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1834-1841.	3.6	58
62	Modified release and conventional glucocorticoids and diurnal androgen excretion in congenital adrenal hyperplasia. Journal of Clinical Endocrinology and Metabolism, 2017, 102, jc.2016-2855.	3.6	38
63	Dysregulation of 11beta-hydroxysteroid dehydrogenases: implications during pregnancy and beyond. Journal of Maternal-Fetal and Neonatal Medicine, 2017, 30, 284-293.	1.5	27
64	Care standards for non-alcoholic fatty liver disease in the United Kingdom 2016: a cross-sectional survey. Frontline Gastroenterology, 2017, 8, 252-259.	1.8	22
65	Cortisol Metabolism as a Regulator of the Tissue-Specific Glucocorticoid Action. , 2017, , 271-301.		0
66	AKR1C3-Mediated Adipose Androgen Generation Drives Lipotoxicity in Women With Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3327-3339.	3.6	133
67	Baseline morning cortisol level as a predictor of pituitary��adrenal reserve: a comparison across three assays. Clinical Endocrinology, 2017, 86, 177-184.	2.4	53
68	11��HSD1 Modulates the Set Point of Brown Adipose Tissue Response to Glucocorticoids in Male Mice. Endocrinology, 2017, 158, 1964-1976.	2.8	26
69	Acute Hypercortisolemia Exerts Depot-Specific Effects on Abdominal and Femoral Adipose Tissue Function. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1091-1101.	3.6	8
70	Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism. JCI Insight, 2017, 2, .	5.0	187
71	Advanced non��alcoholic fatty liver disease and adipose tissue fibrosis in patients with Alstr�m syndrome. Liver International, 2016, 36, 1704-1712.	3.9	23
72	Male 11��HSD1 Knockout Mice Fed Trans-Fats and Fructose Are Not Protected From Metabolic Syndrome or Nonalcoholic Fatty Liver Disease. Endocrinology, 2016, 157, 3493-3504.	2.8	16

#	ARTICLE	IF	CITATIONS
73	THE ANDRO-METABOLIC SIGNATURE OF IIH COMPARED WITH PCOS AND SIMPLE OBESITY. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, e1.46-e1.	1.9	2
74	Cortisol metabolism, postnatal depression and weight changes in the first 12 months postpartum. Clinical Endocrinology, 2016, 85, 881-890.	2.4	24
75	Optimizing human hepatocyte models for metabolic phenotype and function: effects of treatment with dimethyl sulfoxide (DMSO). Physiological Reports, 2016, 4, e12944.	1.7	21
76	Dual-5 α -Reductase Inhibition Promotes Hepatic Lipid Accumulation in Man. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 103-113.	3.6	50
77	Non-alcoholic fatty liver disease and diabetes. Metabolism: Clinical and Experimental, 2016, 65, 1096-1108.	3.4	396
78	Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet, The, 2016, 387, 679-690.	13.7	1,397
79	Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. Journal of Hepatology, 2016, 64, 399-408.	3.7	308
80	SFRP2 Is Associated with Increased Adiposity and VEGF Expression. PLoS ONE, 2016, 11, e0163777.	2.5	27
81	Response to the Letter: "Dual-5 α -Reductase Inhibition Promotes Hepatic Lipid Accumulation in Man". Journal of Clinical Endocrinology and Metabolism, 2016, 101, L48-L49.	3.6	0
82	Gender-Specific Differences in Skeletal Muscle 11 β -HSD1 Expression Across Healthy Aging. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2673-2681.	3.6	67
83	Differential glucocorticoid metabolism in patients with persistent versus resolving inflammatory arthritis. Arthritis Research and Therapy, 2015, 17, 121.	3.5	12
84	Glucocorticoids and non-alcoholic fatty liver disease. Journal of Steroid Biochemistry and Molecular Biology, 2015, 154, 94-103.	2.5	137
85	Association between hypercortisolaemia and adipose tissue blood flow in vivo. Lancet, The, 2015, 385, S63.	13.7	5
86	Tissue Specific Regulation of Glucocorticoids in Severe Obesity and the Response to Significant Weight Loss Following Bariatric Surgery (BARICORT). Journal of Clinical Endocrinology and Metabolism, 2015, 100, 1434-1444.	3.6	35
87	Effect of insulin on AKR1C3 expression in female adipose tissue: in-vivo and in-vitro study of adipose androgen generation in polycystic ovary syndrome. Lancet, The, 2015, 385, S16.	13.7	43
88	5 α -Reductase Type 2 Regulates Glucocorticoid Action and Metabolic Phenotype in Human Hepatocytes. Endocrinology, 2015, 156, 2863-2871.	2.8	38
89	The Dehydrogenase Hypothesis. Advances in Experimental Medicine and Biology, 2015, 872, 353-380.	1.6	19
90	Adrenal suppression in patients taking inhaled glucocorticoids is highly prevalent and management can be guided by morning cortisol. European Journal of Endocrinology, 2015, 173, 633-642.	3.7	116

#	ARTICLE	IF	CITATIONS
91	Diagnosis and management of adrenal insufficiency. <i>Lancet Diabetes and Endocrinology</i> , 2015, 3, 216-226.	11.4	297
92	Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosis. <i>Journal of Clinical Investigation</i> , 2015, 125, 501-520.	8.2	163
93	Differential Adipose Tissue Gene Expression Profiles in Abacavir Treated Patients That May Contribute to the Understanding of Cardiovascular Risk: A Microarray Study. <i>PLoS ONE</i> , 2015, 10, e0117164.	2.5	5
94	Central Hypoadrenalism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 4027-4036.	3.6	80
95	11 β -HSD1 is the major regulator of the tissue-specific effects of circulating glucocorticoid excess. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E2482-91.	7.1	225
96	Severe asymptomatic non-alcoholic fatty liver disease in routine diabetes care; a multi-disciplinary team approach to diagnosis and management. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2014, 107, 33-41.	0.5	41
97	Development of Hepatocellular Carcinoma in a Murine Model of Nonalcoholic Steatohepatitis Induced by Use of a High-Fat/Fructose Diet and Sedentary Lifestyle. <i>American Journal of Pathology</i> , 2014, 184, 1550-1561.	3.8	91
98	Hyperandrogenemia Predicts Metabolic Phenotype in Polycystic Ovary Syndrome: The Utility of Serum Androstenedione. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 1027-1036.	3.6	231
99	IGFALS Gene Dosage Effects on Serum IGF-I and Glucose Metabolism, Body Composition, Bone Growth in Length and Width, and the Pharmacokinetics of Recombinant Human IGF-I Administration. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E703-E712.	3.6	25
100	Abdominal subcutaneous adipose tissue insulin resistance and lipolysis in patients with non-alcoholic steatohepatitis. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 651-660.	4.4	50
101	Longitudinal changes in glucocorticoid metabolism are associated with later development of adverse metabolic phenotype. <i>European Journal of Endocrinology</i> , 2014, 171, 433-442.	3.7	24
102	Understanding androgen action in adipose tissue. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2014, 143, 277-284.	2.5	120
103	Mitotane Therapy in Adrenocortical Cancer Induces CYP3A4 and Inhibits 5 α -Reductase, Explaining the Need for Personalized Glucocorticoid and Androgen Replacement. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 161-171.	3.6	131
104	11 β -Hydroxysteroid Dehydrogenase 1: Translational and Therapeutic Aspects. <i>Endocrine Reviews</i> , 2013, 34, 525-555.	20.1	152
105	Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 234-242.	3.7	204
106	A comparative quality assessment of evidence-based clinical guidelines in endocrinology. <i>Clinical Endocrinology</i> , 2013, 78, 183-190.	2.4	35
107	Regulation of Lipid Metabolism by Glucocorticoids and 11 β -HSD1 in Skeletal Muscle. <i>Endocrinology</i> , 2013, 154, 2374-2384.	2.8	30
108	Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial. <i>BMJ Open</i> , 2013, 3, e003995.	1.9	41

#	ARTICLE	IF	CITATIONS
109	Glucocorticoids Fail to Cause Insulin Resistance in Human Subcutaneous Adipose Tissue In Vivo. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 1631-1640.	3.6	53
110	Dehydroepiandrosterone exerts antiglucocorticoid action on human preadipocyte proliferation, differentiation, and glucose uptake. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2013, 305, E1134-E1144.	3.5	50
111	Mechanisms in endocrinology: Non-alcoholic fatty liver disease in common endocrine disorders. <i>European Journal of Endocrinology</i> , 2013, 169, R27-R37.	3.7	80
112	Loss of 5 α -Reductase Type 1 Accelerates the Development of Hepatic Steatosis but Protects Against Hepatocellular Carcinoma in Male Mice. <i>Endocrinology</i> , 2013, 154, 4536-4547.	2.8	67
113	Hormonal Regulation of Lipogenesis. <i>Vitamins and Hormones</i> , 2013, 91, 1-27.	1.7	15
114	Evidence for a Shift to Anaerobic Metabolism in Adipose Tissue in Efavirenz-Containing Regimens for HIV with Different Nucleoside Backbones. <i>Antiviral Therapy</i> , 2012, 17, 495-507.	1.0	9
115	Lack of Significant Metabolic Abnormalities in Mice with Liver-Specific Disruption of 11 β -Hydroxysteroid Dehydrogenase Type 1. <i>Endocrinology</i> , 2012, 153, 3236-3248.	2.8	61
116	Guidelines for liver transplantation for patients with non-alcoholic steatohepatitis. <i>Gut</i> , 2012, 61, 484-500.	12.1	71
117	The diagnosis of non-alcoholic fatty liver disease: authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 205-206.	3.7	0
118	A Switch in Hepatic Cortisol Metabolism across the Spectrum of Non Alcoholic Fatty Liver Disease. <i>PLoS ONE</i> , 2012, 7, e29531.	2.5	83
119	Regulation of Lipogenesis by Glucocorticoids and Insulin in Human Adipose Tissue. <i>PLoS ONE</i> , 2011, 6, e26223.	2.5	112
120	P86 5 α -reductase-1 knockout promotes steatosis but protects against hepatocarcinogenesis in a murine model of NAFLD. <i>Gut</i> , 2011, 60, A39-A40.	12.1	0
121	Current therapeutic strategies in non-alcoholic fatty liver disease. <i>Diabetes, Obesity and Metabolism</i> , 2011, 13, 692-702.	4.4	92
122	Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 33, 525-540.	3.7	254
123	Short- and long-term glucocorticoid treatment enhances insulin signalling in human subcutaneous adipose tissue. <i>Nutrition and Diabetes</i> , 2011, 1, e3-e3.	3.2	12
124	Cerebrospinal Fluid Corticosteroid Levels and Cortisol Metabolism in Patients with Idiopathic Intracranial Hypertension: A Link between 11 β -HSD1 and Intracranial Pressure Regulation?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 5348-5356.	3.6	84
125	Mortality in Patients with Pituitary Disease. <i>Endocrine Reviews</i> , 2010, 31, 301-342.	20.1	331
126	Low energy diet and intracranial pressure in women with idiopathic intracranial hypertension: prospective cohort study. <i>BMJ: British Medical Journal</i> , 2010, 341, c2701-c2701.	2.3	257

#	ARTICLE	IF	CITATIONS
127	The Role of 11 β -Hydroxysteroid Dehydrogenase 1 in Adipogenesis in Thyroid-Associated Ophthalmopathy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 398-406.	3.6	25
128	Pathogenesis of non-alcoholic fatty liver disease. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2010, 103, 71-83.	0.5	581
129	11 β -Hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 1067-1076.	4.1	44
130	11 β -Hydroxysteroid Dehydrogenase Type 1 Regulates Glucocorticoid-Induced Insulin Resistance in Skeletal Muscle. <i>Diabetes</i> , 2009, 58, 2506-2515.	0.6	146
131	Increased 5 α -Reductase Activity and Adrenocortical Drive in Women with Polycystic Ovary Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 3558-3566.	3.6	97
132	Selective Inhibitors of 11 β -Hydroxysteroid Dehydrogenase Type 1 for Patients With Metabolic Syndrome: Is the Target Liver, Fat, or Both?. <i>Diabetes</i> , 2009, 58, 14-15.	0.6	31
133	Nonclassic Lipoid Congenital Adrenal Hyperplasia Masquerading as Familial Glucocorticoid Deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 3865-3871.	3.6	138
134	Elevated cerebrospinal fluid (CSF) leptin in idiopathic intracranial hypertension (IIH): evidence for hypothalamic leptin resistance?. <i>Clinical Endocrinology</i> , 2009, 70, 863-869.	2.4	69
135	Effects of glucocorticoids on fat mass and the therapeutic potential of targeting 11 β -hydroxysteroid dehydrogenase type 1 in obesity. <i>Clinical Lipidology</i> , 2009, 4, 439-447.	0.4	0
136	Adipocyte differentiation, mitochondrial gene expression and fat distribution: differences between zidovudine and tenofovir after 6 months. <i>Antiviral Therapy</i> , 2009, 14, 1089-1100.	1.0	25
137	11 β -Hydroxysteroid dehydrogenase type 1 regulates insulin and glucagon secretion in pancreatic islets. <i>Diabetologia</i> , 2008, 51, 2003-2011.	6.3	51
138	Adrenal suppression in bronchiectasis and the impact of inhaled corticosteroids. <i>European Respiratory Journal</i> , 2008, 32, 1047-1052.	6.7	34
139	Reduced Glucocorticoid Production Rate, Decreased 5 α -Reductase Activity, and Adipose Tissue Insulin Sensitization After Weight Loss. <i>Diabetes</i> , 2008, 57, 1536-1543.	0.6	79
140	Impaired Glucose Tolerance and Insulin Resistance Are Associated With Increased Adipose 11 β -Hydroxysteroid Dehydrogenase Type 1 Expression and Elevated Hepatic 5 α -Reductase Activity. <i>Diabetes</i> , 2008, 57, 2652-2660.	0.6	117
141	Lack of Hexose-6-Phosphate Dehydrogenase Impairs Lipid Mobilization from Mouse Adipose Tissue. <i>Endocrinology</i> , 2008, 149, 2584-2591.	2.8	35
142	Steroid Biomarkers and Genetic Studies Reveal Inactivating Mutations in Hexose-6-Phosphate Dehydrogenase in Patients with Cortisone Reductase Deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 3827-3832.	3.6	79
143	A novel selective 11 β -hydroxysteroid dehydrogenase type 1 inhibitor prevents human adipogenesis. <i>Journal of Endocrinology</i> , 2008, 197, 297-307.	2.6	80
144	Inhibition of 11 β -Hydroxysteroid Dehydrogenase Type 1 Activity in Vivo Limits Glucocorticoid Exposure to Human Adipose Tissue and Decreases Lipolysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 857-864.	3.6	92

#	ARTICLE	IF	CITATIONS
145	Reduced 11 β -hydroxysteroid dehydrogenase type 1 activity in obese boys. <i>European Journal of Endocrinology</i> , 2007, 157, 319-324.	3.7	21
146	11 β -Hydroxysteroid Dehydrogenase Type 1 Regulation by Intracellular Glucose 6-Phosphate Provides Evidence for a Novel Link between Glucose Metabolism and Hypothalamo-Pituitary-Adrenal Axis Function. <i>Journal of Biological Chemistry</i> , 2007, 282, 27030-27036.	3.4	48
147	Characterisation of 11 β -hydroxysteroid dehydrogenase 1 in human orbital adipose tissue: a comparison with subcutaneous and omental fat. <i>Journal of Endocrinology</i> , 2007, 192, 279-288.	2.6	32
148	Glucocorticoid Modulation of Insulin Signaling in Human Subcutaneous Adipose Tissue. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 4332-4339.	3.6	60
149	Modulation of glucocorticoid action and the treatment of type-2 diabetes. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2007, 21, 607-619.	4.7	53
150	Corticosteroids, 11 β -Hydroxysteroid Dehydrogenase Isozymes and the Rabbit Choroid Plexus. <i>Journal of Neuroendocrinology</i> , 2007, 19, 614-620.	2.6	42
151	Depot-specific prostaglandin synthesis in human adipose tissue: A novel possible mechanism of adipogenesis. <i>Gene</i> , 2006, 380, 137-143.	2.2	46
152	The Long-Term Predictive Accuracy of the Short Synacthen (Corticotropin) Stimulation Test for Assessment of the Hypothalamic-Pituitary-Adrenal Axis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 43-47.	3.6	125
153	Expression profiling of 11 β -hydroxysteroid dehydrogenase type-1 and glucocorticoid-target genes in subcutaneous and omental human preadipocytes. <i>Journal of Molecular Endocrinology</i> , 2006, 37, 327-340.	2.5	53
154	Hexose-6-phosphate dehydrogenase confers oxo-reductase activity upon 11 β -hydroxysteroid dehydrogenase type 1. <i>Journal of Molecular Endocrinology</i> , 2005, 34, 675-684.	2.5	153
155	11 β -Hydroxysteroid dehydrogenase type 1 as a therapeutic target in the metabolic syndrome. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2005, 2, 93-96.	0.5	5
156	Mechanisms of Disease: selective inhibition of 11 β -hydroxysteroid dehydrogenase type 1 as a novel treatment for the metabolic syndrome. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2005, 1, 92-99.	2.8	68
157	11 β -hydroxysteroid dehydrogenase type 1 in human disease: a novel therapeutic target. <i>Minerva Endocrinologica</i> , 2005, 30, 37-46.	1.8	5
158	11 β -Hydroxysteroid Dehydrogenase Type 1 Activity in Lean and Obese Males with Type 2 Diabetes Mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 4755-4761.	3.6	153
159	Weight Loss Increases 11 β -Hydroxysteroid Dehydrogenase Type 1 Expression in Human Adipose Tissue. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 2711-2716.	3.6	85
160	Androgen generation in adipose tissue in women with simple obesity – a site-specific role for 17 β -hydroxysteroid dehydrogenase type 5. <i>Journal of Endocrinology</i> , 2004, 183, 331-342.	2.6	154
161	“Cushing’s disease of the omentum” Fat or fiction?. <i>Journal of Endocrinological Investigation</i> , 2004, 27, 171-174.	3.3	24
162	11 β -Hydroxysteroid Dehydrogenase Type 1: A Tissue-Specific Regulator of Glucocorticoid Response. <i>Endocrine Reviews</i> , 2004, 25, 831-866.	20.1	897

#	ARTICLE	IF	CITATIONS
163	Mutations in the genes encoding 11 β -hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency. <i>Nature Genetics</i> , 2003, 34, 434-439.	21.4	276
164	Treating Hypertension in Diabetic Nephropathy. <i>Diabetes Care</i> , 2003, 26, 1802-1805.	8.6	24
165	Low-Dose Growth Hormone Inhibits 11 β -Hydroxysteroid Dehydrogenase Type 1 but Has No Effect upon Fat Mass in Patients with Simple Obesity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 2113-2118.	3.6	39
166	Expression of 11 β -Hydroxysteroid Dehydrogenase Type 1 in Adipose Tissue Is Not Increased in Human Obesity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 5630-5635.	3.6	196
167	Absence of Cushingoid Phenotype in a Patient with Cushing's Disease due to Defective Cortisone to Cortisol Conversion. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 57-62.	3.6	61
168	The Functional Consequences of 11 β -Hydroxysteroid Dehydrogenase Expression in Adipose Tissue. <i>Hormone and Metabolic Research</i> , 2002, 34, 746-751.	1.5	38
169	Cortisol, 11 β -hydroxysteroid dehydrogenase type 1 and central obesity. <i>Trends in Endocrinology and Metabolism</i> , 2002, 13, 94-96.	7.1	43
170	11 β -HYDROXYSTEROID DEHYDROGENASE TYPE 1 IN DIFFERENTIATING OMENTAL HUMAN PREADIPOCYTES: FROM DE-ACTIVATION TO GENERATION OF CORTISOL. <i>Endocrine Research</i> , 2002, 28, 449-461.	1.2	64
171	Absence of Cushingoid Phenotype in a Patient with Cushing's Disease due to Defective Cortisone to Cortisol Conversion. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 57-62.	3.6	48
172	Cortisol metabolism and the role of 11 β -hydroxysteroid dehydrogenase. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2001, 15, 61-78.	4.7	129
173	Association between premature mortality and hypopituitarism. <i>Lancet</i> , The, 2001, 357, 425-431.	13.7	930
174	Growth Hormone, Insulin-Like Growth Factor-I and the Cortisol-Cortisone Shuttle. <i>Hormone Research in Paediatrics</i> , 2001, 56, 1-6.	1.8	61
175	Regulation of Expression of 11 β -Hydroxysteroid Dehydrogenase Type 1 in Adipose Tissue: Tissue-Specific Induction by Cytokines*. <i>Endocrinology</i> , 2001, 142, 1982-1989.	2.8	215
176	Regulation of Expression of 11 β -Hydroxysteroid Dehydrogenase Type 1 in Adipose Tissue: Tissue-Specific Induction by Cytokines. <i>Endocrinology</i> , 2001, 142, 1982-1989.	2.8	63
177	The Role of 11 β -Hydroxysteroid Dehydrogenase in Central Obesity and Osteoporosis. <i>Endocrine Research</i> , 2000, 26, 711-722.	1.2	37
178	Gender specific metabolic phenotype in the 5[beta]-reductase knockout mouse. <i>Endocrine Abstracts</i> , 0, ,.	0.0	1